Background
Patients with neuroblastoma due to the amplification of a 130-kb genomic DNA region containing the MYCN oncogene have poor prognoses.
Methods
Bioinformatics data were used to discover a novel long noncoding RNA, lncUSMycN, at the 130-kb amplicon. RNAprotein pull-down assays were used to identify proteins bound to lncUSMycN RNA. Kaplan-Meier survival analysis, multivariable Cox regression, and two-sided log-rank test were used to examine the prognostic value of lncUSMycN and NonO expression in three cohorts of neuroblastoma patients (n = 47, 88, and 476, respectively). Neuroblastoma-bearing mice were treated with antisense oligonucleotides targeting lncUSMycN (n = 12) or mismatch sequence (n = 13), and results were analyzed by multiple comparison two-way analysis of variance. All statistical tests were two-sided.
Results
Bioinformatics data predicted lncUSMycN gene and RNA, and reverse-transcription polymerase chain reaction confirmed its three exons and two introns. The lncUSMycN gene was coamplified with MYCN in 88 of 341 human neuroblastoma tissues. lncUSMycN RNA bound to the RNA-binding protein NonO, leading to N-Myc RNA upregulation and neuroblastoma cell proliferation. High levels of lncUSMycN and NonO expression in human neuroblastoma tissues independently predicted poor patient prognoses (lncUSMycN: hazard ratio [HR] = 1.87, 95% confidence interval [CI] = 1.06 to 3.28, P = .03; NonO: HR = 2.48, 95% CI = 1.34 to 4.57, P = .004). Treatment with antisense oligonucleotides targeting lncUSMycN in neuroblastoma-bearing mice statistically significantly hindered tumor progression (P < .001).
Conclusions
Our data demonstrate the important roles of lncUSMycN and NonO in regulating N-Myc expression and neuroblastoma oncogenesis and provide the first evidence that amplification of long noncoding RNA genes can contribute to tumorigenesis. JNCI J Natl Cancer Inst (2014) 106(7): dju113 doi:10.1093/jnci/dju113
Cancer is the most common cause of death from disease in children, and neuroblastoma is the most common solid tumor in early childhood. Amplification of a 130-kb core genomic DNA region containing the MYCN oncogene is a clonal feature in 25% to 30% of human neuroblastoma tissues (1) . Myc oncoproteins, including N-Myc and c-Myc, induce cell proliferation, malignant transformation, and tumor progression (2) (3) (4) .
At least 90% of the human genome is transcribed to generate an extraordinary range of non-protein-coding (noncoding) RNAs, including long noncoding RNAs (lncRNAs) (5) (6) (7) . Although more than 10 000 human lncRNAs have been predicted by bioinformatics analyses or identified by cDNA/RNA sequencing analyses, less than 1% have been experimentally characterized (7) (8) (9) . Recent studies have demonstrated that the expression of lncRNAs is regulated by key transcription factors (7, 10) and by biological processes such as cell differentiation (11) and that lncRNAs play key roles in cancer cell proliferation, survival, invasion, and metastasis by regulating gene expression (10, (12) (13) (14) (15) (16) (17) .
Although the MYCN oncogene has been extensively studied in the last three decades, it is unknown whether other genomic elements within the 130-kb amplicon containing MYCN play a role in neuroblastoma tumorigenesis. Here we identified a novel lncRNA upstream of MYCN, lncUSMycN, transcribed from the 130-kb amplicon, and found that lncUSMycN upregulated N-Myc mRNA expression by binding to NonO protein.
Balb/c mice aged 5 to 6 weeks were injected subcutaneously with 10 7 Kelly human neuroblastoma cells into the flanks. When tumors reached 0.05 g, the mice were injected intraperitoneally with locked nucleic acid (LNA)-antisense oligonucleotide (LNA-ASO) targeting lncUSMycN (lncUSMycN LNA-ASO) or control LNA-ASO at 50 mg/kg every second day for 2 weeks. Tumor mass was measured and calculated. The mice were killed at the end of the 14-day therapy, and tumor tissues were collected, weighed, formalin fixed, and paraffin embedded for immunohistochemistry analysis.
Patient Tumor Sample Analysis
Forty-seven primary neuroblastoma cDNA samples synthesized from tumors from untreated patients were obtained from Children's Cancer Institute Australia and had been studied previously (Supplementary Table 1 , available online) (18) . The study was approved by Sydney Children's Hospitals Network Human Research Ethics Committee, and written informed consent was waived because samples were collected before 2003. The International Neuroblastoma Staging System (22) was used to classify disease stage. Sex and racial/ethnic groups were not analyzed because they were not prognostic factors for neuroblastoma (22) . lncUSMycN, NonO, and N-Myc expression in neuroblastoma tissues were also analyzed in 88 (Versteeg dataset) and 476 (Kocak dataset) human neuroblastoma samples in the publically available gene expression databases (http://r2.amc.nl, last accessed August 26, 2013) . Clinical information for the 88 patients in the Versteeg dataset was directly downloaded from http://r2.amc.nl, last accessed August 26, 2013, and clinical information for the 476 patients in the Kocak dataset was obtained from the authors' previous publications (19, 20) .
Statistical Procedures
Experiments were repeated at least three times. All data for statistical analysis were calculated as mean ± standard deviation (SD). Differences were analyzed for statistical significance using two-sided unpaired t test for two groups or multiple comparison one-way or two-way analysis of variance (ANOVA) for more than two groups.
Correlation between N-Myc expression and lncUSMycN or NonO expression in human neuroblastoma tissues was examined with Pearson's correlation. For patient prognosis studies, overall survival was defined as the time from diagnosis until death or until last contact if the patient did not die. The patient cohort was dichotomized into two groups (low vs high lncUSMycN or NonO expression) on the basis of the median or high decile value of lncUSMycN or NonO in the cohort. Survival analyses were performed according to the method of Kaplan and Meier, and comparisons of survival curves were made using two-sided log-rank tests (21) . Multivariable Cox regression analyses were performed to determine whether lncUSMycN and NonO expression in human neuroblastoma tissues predicted patient prognosis independent of patient age, disease stage (22) , and MYCN gene amplification status. Probabilities of survival and hazard ratios (HRs) were provided with 95% confidence intervals (CIs). Proportionality was confirmed by visual inspection of the plots of log(2log(S(time))) vs log(time), which were observed to remain parallel.
A probability value of .05 or less was considered statistically significant. All statistical tests were two-sided.
Additional methods are provided as Supplementary Methods (available online).
results

Identification of Full-Length lncUSMycN RNA
By extracting bioinformatics data generated by the HAVANA team at the Sanger Institute, we found a novel lncRNA upstream of MYCN, which we named lncUSMycN, within the 130-kb amplicon containing the MYCN oncogene ( Figure 1A ; Supplementary Figure 1A , available online). To identify the full-length lncUSMycN RNA, we first performed reverse-transcription polymerase chain reaction (RT-PCR) with primers targeting the beginning of exon 1 and the end of exon 3. Sequencing analysis revealed that the PCR product matched the 3 exons of lncUSMycN without incorporation of the two introns ( Figure 1B; Supplementary Figure 1A , available online). We then performed rapid amplification of cDNA ends (RACE) PCR to amplify the 5' and 3' ends of lncUSMycN. Sequencing of the RACE PCR products revealed an extra 140-bp sequence upstream of the first exon (Supplementary Figure 1B , available online).
To confirm that lncUSMycN does not encode a protein, we cloned the full-length lncUSMycN into pcDNA3.1+ construct and performed in vitro translation assays. The assays showed that lncUSMycN did not have protein-coding potential, whereas positive control tissue transglutaminase and T7 expression constructs gave rise to proteins ( Figure 1C) .
We next used the publically available single nucleotide polymorphism array data from human neuroblastoma tissues, which were originally generated by the Therapeutically Applicable Research to Generate Effective Treatments initiative (https://target-data.nci. nih.gov/, last accessed June 12, 2013) . Gene copy number analysis revealed that MYCN amplification was observed in 89 of 341 (26.1%) samples for data which passed quality control, whereas lncUSMycN was amplified in 88 of the 341 (25.8%) samples (Supplementary  Tables 2 and 3 , available online). Importantly, although all the lncUSMycN gene-amplified neuroblastoma tissues displayed MYCN gene amplification, only one of the 89 MYCN-amplified tumor tissues did not show concomitant lncUSMycN amplification.
We next examined lncUSMycN expression in human neuroblastoma cell lines and tumor tissues. RT-PCR analyses showed that lncUSMycN RNA was expressed in the MYCN-amplified IMR32, BE2C, SK-N-DZ, CHP134, and Kelly neuroblastoma cells but was undetectable in MYCN nonamplified SK-N-FI, SK-N-AS, NB69, SY5Y, and SHEP, as well as MYCN-amplified LAN-1 neuroblastoma cells ( Figure 1D , available online). Furthermore, RT-PCR analysis of 47 human neuroblastoma tissues (Supplementary Table 1 , available online) showed that lncUSMycN RNA was detectable in nine of 10 MYCN-amplified, but only four of 37 MYCN nonamplified, human neuroblastoma tissues ( Figure 1E ). Taken together, the data confirm that the lncUSMycN gene is frequently coamplified with MYCN and that lncUSMycN RNA is overexpressed in MYCN oncogene-amplified human neuroblastoma cell lines and tumor tissues.
Effect of lncUSMycN on N-Myc Expression
lncRNAs are well-known to regulate the expression of neighboring protein-coding genes (11, 14, 29) . We therefore examined whether lncUSMycN regulated N-Myc expression. As shown in Figure 2 
lncUSMycN in Neuroblastoma Cell Proliferation and as a Prognostic Marker
We next investigated whether lncUSMycN was differentially expressed at different phases of the cell cycle and regulated cell proliferation. BE2C neuroblastoma cells were synchronized at G 0 , G 1 , G 1 /S, S, G 2 /M, or mitosis phase as we described previously (30) . As shown in Figure 3A , lncUSMycN RNA was expressed at the lowest in cells at G0 phase and the highest in cells at G1/S and S phases. Alamar blue assays showed that lncUSMycN siRNAs reduced the numbers of viable Kelly We showed in Figure 1 that lncUSMycN expression in a cohort of 47 human neuroblastoma tissues associated with N-Myc expression. Kaplan-Meier analysis showed that patients with neuroblastoma tissues exhibiting high levels of lncUSMycN expression had poor survival rates (HR = 4.29; 95% CI = 1.46 to 24.79; P = .01) ( Figure 3D ). Additionally, analyses of the publically available (http://r2.amc.nl, last accessed August 26, 2013) Versteeg and Kocak (19, 20) Relative cell numbers were examined by Alamar blue assays and expressed as percentage changes in cell numbers. One-way analysis of variance was used to determine statistical significance. D) RT-PCR studies were performed in 47 human neuroblastoma cDNA samples with primers targeting lncUSMycN. Kaplan-Meier curves showed the probability of overall survival according to the level of lncUSMycN expression in the 47 neuroblastoma patients. P value was obtained from two-sided log-rank test. E) Two-sided Pearson's correlation was used to analyze correlation between lncUSMycN expression and N-Myc expression in tumor tissues from 88 and 476 neuroblastoma patients in the publically available microarray gene expression Versteeg dataset and Kocak dataset, respectively, which were downloaded from R2 microarray analysis and visualization platform (http:// r2.amc.nl, last accessed August 26, 2013). F) Kaplan-Meier curves showed the probability of overall survival of patients according to the level of lncUSMycN expression in the 88 and 476 neuroblastoma patients in the Versteeg and Kocak datasets, respectively. CI = confidence interval; HR = hazard ratio. P value was obtained from twosided log-rank test. Error bars represent standard deviation. *P < .001. 
Modulation of N-Myc mRNA Expression by the Interaction Between lncUSMycN and NonO
To identify the mechanism by which lncUSMycN increased N-Myc mRNA expression, we in vitro transcribed lncUSMycN RNA from the pcDNA3.1-lncUSMycN expression construct and labeled the RNA with biotin, followed by incubation with Kelly cell protein lysates. Mass spectrometry analyses showed that lncUSMycN RNA specifically bound to proteins, including KHSRP, hnRNPU, FUBP1, and NonO (Supplementary Table 4 , available online).
RT-PCR studies showed that knocking down the expression of NonO, but not KHSRP, hnRNPU or FUBP1, modulated N-Myc mRNA expression (Supplementary Figure 4, available online) . We next performed RNA immunoprecipitation assays with an anti-NonO antibody or control antibody and Kelly cell lysates. Immunoblot and RT-PCR analyses showed that the NonO antibody indeed pulled down NonO protein ( Figure 4A ) and efficiently pulled down lncUSMycN RNA, N-Myc RNA, and the positive control FOS RNA, but not the negative control U1 RNA ( Figure 4B ).
We then transfected Kelly and BE2C cells with control siRNA, NonO siRNA-1, or NonO siRNA-2. RT-PCR and immunoblot analyses showed that NonO siRNAs reduced N-Myc mRNA expression in Kelly (mean fold of control ± SD: NonO siRNA-1, 0.57 ± 0.01; NonO siRNA-2, 0.61 ± 0.01) and BE2C cells (mean fold of control ± SD: NonO siRNA-1, 0.33 ± 0.03; NonO siRNA-2, 0.57 ± 0.07; P < .001, one-way ANOVA) ( Figure 4C) , and decreased N-Myc protein expression ( Figure 4D ). We next transfected SK-N-AS cells with control siRNA or NonO siRNA-1, followed by cotransfection with an N-Myc-expressing construct and/or a lncUSMycN-expressing construct. RT-PCR and immunoblot analysis showed that the lncUSMycN expression construct increased N-Myc mRNA and protein expression in cells cotransfected with control siRNA, but not in cells cotransfected with NonO siRNA-1 ( Figure 4E ; Supplementary Figure 4E , available online). Moreover, chromatin immunoprecipitation assays showed that immunoprecipitation with an anti-NonO antibody did not enrich DNA fragments at the MYCN gene promoter ( Figure 4F ), and Alamar blue assays revealed that NonO siRNAs reduced proliferation in Kelly and BE2C cells ( Figure 4G ). Taken together, the data indicate that NonO protein binds to lncUSMycN RNA and N-Myc RNA, upregulates N-Myc expression, and induces neuroblastoma cell proliferation and that lncUSMycN upregulates N-Myc mRNA expression by binding to NonO protein.
Prognostic Significance of NonO Expression in Primary Neuroblastoma
We next examined NonO mRNA expression in the cohort of 47 neuroblastoma cDNA samples (Supplementary Table 1 , available online). RT-PCR analysis revealed that NonO mRNA expression correlated with N-Myc mRNA expression (R = 0.642; 95% CI = 0.437 to 0.783; P < .001) ( Figure 5A ), and Kaplan-Meier analysis showed that high levels of NonO mRNA expression in tumor tissues associated with poor patient prognosis (HR = 4.34; 95% CI = 1.63 to 39.07; P = .01) ( Figure 5B) . Consistently, the publicly available (http://r2.amc.nl, last accessed August 26, 2013) Versteeg and Kocak (19, 20) microarray gene expression datasets from 88 and 476 patients both showed that NonO mRNA expression in human neuroblastoma tissues correlated with N-Myc mRNA expression (Versteeg dataset: R = 0.638, 95% CI = 0.494 to 0.747, P < .001; Kocak dataset: R = 0.504, 95% CI = 0.434 to 0.568, P < .001) ( Figure 5C ) and that high levels of NonO mRNA expression in tumor tissues associated with poor patient prognoses, using the mean of NonO expression as cut points (Versteeg dataset: HR = 10.51, 95% CI = 3.76 to 15.05, P < .001; Kocak dataset: HR = 6.76, 95% CI = 3.69 to 8.51, P < .001) ( Figure 5D ). Importantly, in the 72 MYCN-amplified human neuroblastoma tissues of the Kocak dataset, NonO mRNA expression also correlated with N-Myc mRNA expression (R = 0.558; 95% CI = 0.375 to 0.700; P < .001) ( Figure 5E ), and high levels of NonO mRNA expression in tumor tissues associated with poor patient prognosis (HR = 2.04; 95% CI = 1.04 to 6.16; P = .04) ( Figure 5F ). Additionally, high levels of lncUSMycN and NonO expression in neuroblastoma tissues strongly associated with reduced overall survival, independent of disease stage, age at the time of diagnosis, and MYCN oncogene amplification (lncUSMycN: HR = 1.87, 95% CI = 1.06 to 3.28, P = .03; NonO, HR = 2.48, 95% CI = 1.34 to 4.57, P = .004; multivariable Cox regression and two-sided log-rank test) ( Table 1) . Consistently, high levels of lncUSMycN expression in neuroblastoma tissues positively associated with reduced overall survival in 404 MYCN-nonamplified patients of the Kocak dataset (HR = 2.00; 95% CI = 1.05 to 5.65; P = .04) (Supplementary Figure 5 , available online).
lncUSMycN Expression and Neuroblastoma Progression in Mice
We next designed LNA-ASO (31) targeting lncUSMycN (lncUSMycN LNA-ASO) and control LNA-ASO. RT-PCR studies confirmed that transfection with lncUSMycN LNA-ASO efficiently reduced lncUSMycN RNA expression in Kelly and BE2C neuroblastoma cells ( Figure 6A ). Consistent with data from lncUSMycN siRNAs, lncUSMycN LNA-ASO statistically significantly reduced N-Myc mRNA and protein expression, as well as proliferation in neuroblastoma cells ( Figure 6 , B and C).
We then xenografted Kelly neuroblastoma cells into nude mice and treated the mice with lncUSMycN LNA-ASO (n = 12 intraperitoneally with control LNA-ASO (n = 13 mice) or lncUSMycN LNA-ASO (n = 12 mice) at 50 mg/kg every second day for 2 weeks. For the left panel, tumor masses were monitored in live mice every second day, and multiple-comparison two-way analysis of variance was used to determine statistical significance. For the right panel, tumors were weighed after the mice were killed, and two-sided t test was used to determine statistical significance. E) Tumor tissues from four mice treated with control LNA-ASO or lncUSMycN LNA-ASO were immunostained with an anti-N-Myc antibody and visualized with diaminobenzidine (brown). The nuclei were counterstained with hematoxylin (blue). N-Myc protein expression was semiquantified and expressed as histology scores. Two-sided t test was used to determine statistical significance. Scale bars represent 10 µm. Error bars represent standard deviation. *P < .001; †P < .05.
mice) or control LNA-ASO (n = 13 mice). As shown in Figure 6D , treatment with lncUSMycN LNA-ASO statistically significantly reduced neuroblastoma mass (mean tumor mass ± SD: day 12, control LNA-ASO, 1384. Figure 6E) . These results therefore demonstrate that lncUSMycN plays an important role in neuroblastoma progression, at least partly through upregulating N-Myc expression.
Discussion
The lncRNA ncRAN acts like an oncogene in aggressive neuroblastoma (32) , and the lncRNA transcribed ultraconserved regions are involved in diverse cellular processes, such as p53 response and proliferation, in neuroblastoma (33) . (11, 14, 29) . In this study, we found that knocking down lncUSMycN expression with siRNAs reduces N-Myc mRNA and protein expression in MYCN oncogene-amplified neuroblastoma cells and that ectopic lncUSMycN expression in MYCN-nonamplified neuroblastoma cells increases exogenous N-Myc mRNA and protein expression. Because knocking down lncUSMycN expression does not affect the presence of trimethyl-H3K4 at the MYCN gene promoter, lncUSMycN upregulates N-Myc expression through a post-transcriptional mechanism.
Myc oncoproteins are well known to exert tumorigenic effects through inducing cell proliferation (39, 40) . In this study, analysis of lncUSMycN expression in neuroblastoma cells shows that lncUSMycN is expressed at the highest levels at G1/S and S phases of the cell cycle, and cell proliferation assays confirm that knocking down lncUSMycN expression in neuroblastoma cells results in growth inhibition. Importantly, this study further shows that knocking down lncUSMycN expression reduces N-Myc expression in tumor tissues and hinders tumor progression in neuroblastoma-bearing mice. Taken together, our in vitro and in vivo data suggest that lncUSMycN plays important roles in N-Myc expression, cell proliferation, and tumorigenesis and that lncUSMycN is a novel target for the therapy of neuroblastoma.
In this study, we have identified NonO as one of the proteins bound to lncUSMycN RNA. NonO enhances mRNA maturation (41) , regulates mRNA nuclear retention and post-transcriptional processing (42) (43) (44) , and upregulates mRNAs through binding to Sox9 or Instability Elements (41, 45) . This study shows that NonO binds to both lncUSMycN RNA and N-Myc RNA and that silencing NonO expression blocks lncUSMycN-induced N-Myc mRNA and protein overexpression. Our data indicate that lncUSMycN increases N-Myc mRNA expression through binding to NonO, which post-transcriptionally upregulates N-Myc expression. Importantly, this study further confirms that a high level of NonO expression in human neuroblastoma tissues correlates with a high level of N-Myc expression, advanced disease stage, and poor prognosis. These data therefore demonstrate that a high level of NonO expression in human neuroblastoma tissues can be used as a marker for poor prognosis and that NonO is a novel therapeutic target.
A limitation of this study is the lack of therapeutic application of the discoveries at the moment. Future studies are required to identify clinically applicable small molecule compounds that block the interaction between lncUSMycN and NonO and reduce N-Myc expression and neuroblastoma progression. 
